Cipla Ltd Analyst Rating
based on 36 analysts
61.11%
Buy
22.22%
Hold
16.67%
Sell
Based on 36 analysts offering long term price targets for Cipla Ltd. An average target of ₹1634.61
Source: S&P Global Market Intelligence
Cipla Ltd Share analysis
Cipla Ltd price forecast by 36 analysts
Upside of2.64%
High
₹1960
Target
₹1634.61
Low
₹1204
Cipla Ltd target price ₹1634.61, a slight upside of 2.64% compared to current price of ₹1592.6. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla Ltd revenue growth forecast
Expected growth rate Q1, FY2026:16.84%
Forecast
Actual
Including amortisation and stock based compensations
Cipla Ltd EPS growth forecast
EPS estimate Q1, FY2026:25.74%
Forecast
Actual
Source: S&P Global Market Intelligence
Cipla Ltd Performance
Day's Low
Day's High
₹1,568.7₹1,597.7552 Week's Low
52 Week's High
₹1,164.55₹1,702.05
| Returns % | |
| 1 Month Return | -5.23 % |
| 3 Month Return | + 1.13 % |
| 1 Year Return | + 28.63 % |
| Market Stats | |
| Previous Close | ₹1,576.15 |
| Open | ₹1,575.10 |
| Volume | 17.18L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,27,289.16Cr |
Cipla Ltd Key Statistics
| P/E Ratio | 28.74 |
| PEG Ratio | 2.27 |
| Market Cap | ₹1,27,289.16 Cr |
| P/B Ratio | 4.31 |
| EPS | 51.47 |
| Dividend Yield | 0.87 |
| Sector | Pharmaceuticals |
| ROE | 15.5 |
Cipla Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,27,289.16 Cr | 50.03% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,58,217.95 Cr | 49.57% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,07,043.79 Cr | 50.97% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹39,379.68 Cr | 4.39% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,717.92 Cr | -0.46% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Cipla Ltd
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Share Price: ₹1592.60 per share as on 08 Nov, 2024 04:01 PM
Market Capitalisation: ₹1,27,289.16Cr as of today
Revenue: ₹6,961.22Cr as on September 2024 (Q3 24)
Net Profit: ₹1,306.02Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Cipla Ltd
Cipla Targets Growth Amid Supply Challenges - 05 Nov, 2024
Cipla is addressing slow seasonal growth in its One India business while managing supply issues with generic Lanreotide. The company anticipates recovery in Q4 FY25. Analysts maintain an ACCUMULATE rating with a target price of INR 1,680/share, reflecting confidence in future growth.
Cipla Stock Rises on Positive FDA Goa Facility News - 04 Nov, 2024
Cipla's stock surged following the USFDA's VAI classification of its Goa facility, enhancing prospects for drug launches like gAbraxane. Brokerages upgraded ratings, citing growth potential despite existing challenges. The stock closed up 1.63% on November 4, 2024.
Cipla Shares Surge After USFDA VAI Status - 31 Oct, 2024
Cipla shares jumped nearly 10% following the USFDA's Voluntary Action Indicated (VAI) status for its Goa facility, alleviating regulatory concerns and paving the way for new product launches, including a generic version of Abraxane. The stock's positive momentum reflects market confidence in Cipla's growth potential in the oncology segment.
Cipla Faces Challenges Despite Q2 Profit Growth - 30 Oct, 2024
Cipla reported a 15% increase in net profit for Q2, but faced challenges including weak domestic sales and supply issues. Analysts cut target prices, leading to a decline in share price. UBS and other brokerages express concerns over future growth prospects.
Cipla Reports Strong Q2 Results Amid Challenges - 29 Oct, 2024
Cipla's Q2 results show a 17% net profit increase to ₹1,303 crore, despite regulatory delays affecting key drug launches. Promoter Kamil Hamied returns to the board.
Cipla Q2 Preview Indicates Modest Growth - 28 Oct, 2024
Analysts anticipate Cipla's Q2FY25 results to show low single-digit growth in sales and profit, with net profit expected at Rs 1,174 crore, a 1.55% YoY increase. Revenue may rise 4.1% YoY to Rs 6,957 crore, but margins could be impacted by lower US sales. Overall, a 3% YoY growth in sales is projected.
Cipla Completes Acquisition of Stake in Cipla Jiangsu - 25 Oct, 2024
Cipla has successfully completed the acquisition of an additional 6.9% equity interest in Cipla Jiangsu Pharmaceuticals, making it a wholly owned step-down subsidiary as of October 25, 2024.
Cipla Faces Challenges Amid Regulatory Delays - 11 Oct, 2024
Cipla's stock has faced downward pressure due to regulatory delays at its Goa facility affecting the launch of Abraxane. Despite maintaining a Buy rating, brokerages express concerns over competition from a Chinese generic version. The stock has seen a notable decline following a downgrade from Nomura, highlighting potential revenue impacts.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 939.04 Cr → 1.30K Cr (in ₹), with an average increase of 14.9% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 27.77% to 28.74% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 6.41K Cr → 7.24K Cr (in ₹), with an average increase of 5.9% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 125.8% return, outperforming this stock by 51.6%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 70.1% return, outperforming this stock by 41.4%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 30.86% of holdings in Sep 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 1 month, CIPLA stock has moved down by -5.2%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 16.30% to 16.08% in Sep 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 17.59% to 17.44% in Sep 2024 quarter
News
Top Gainers and Losers today on 30 July, 2024: Tata Motors, NTPC, LTI Mindtree, Cipla among most active stocks; Check full list here
Top Gainers and Losers Today : The Sensex gained 99.56 points, or 0.12, to settle at 81355.84, while the Nifty gained 21.2 points, or 0.09, to close at 24836.1.30 Jul, 2024 04:03 PMBuy Cipla; target of Rs 1830: Motilal Oswal
Motilal Oswal is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1830 in its research report dated July 26, 2024.30 Jul, 2024 10:18 PMAccumulate Cipla; target of Rs 1680: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Cipla with a target price of Rs 1680 in its research report dated July 28, 2024.31 Jul, 2024 10:54 AMCipla Ltd Financials
Index Inclusions
Cipla Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 30.86% | ||
| Foreign Institutions | 28.74% | 3.49 | |
| Mutual Funds | 17.44% | ||
| Retail Investors | 16.08% | ||
| Others | 6.89% |
Cipla Ltd Key Indicators
Cipla Ltd Valuation
Cipla Ltd in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (28.74x)
November 8, 2024
Industry (56.93x)
November 8, 2024
Highest (42.80x)
January 23, 2018
Cipla Ltd Earnings and Dividends
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 15.18% since last year same period to ₹1,302.53Cr in the Q2 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 10.61% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.35%.
Read More about Dividends
Cipla Ltd Technicals Summary
Bearish
Neutral
Bullish
Cipla Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Cipla Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Cipla Ltd shares.
Cipla Ltd (CIPLA) share price today is ₹1592.6
Cipla Ltd is listed on NSE
Cipla Ltd is listed on BSE
- Today’s highest price of Cipla Ltd is ₹1597.75.
- Today’s lowest price of Cipla Ltd is ₹1568.7.
PE Ratio of Cipla Ltd is 28.74
PE ratio = Cipla Ltd Market price per share / Cipla Ltd Earnings per share
Today’s traded volume of Cipla Ltd(CIPLA) is 17.18L.
Today’s market capitalisation of Cipla Ltd(CIPLA) is ₹127289.16Cr.
| Cipla Ltd(CIPLA | Price |
|---|---|
52 Week High | ₹1702.05 |
52 Week Low | ₹1164.55 |
Cipla Ltd(CIPLA) share price is ₹1592.6. It is down -6.43% from its 52 Week High price of ₹1702.05
Cipla Ltd(CIPLA) share price is ₹1592.6. It is up 36.76% from its 52 Week Low price of ₹1164.55
| Cipla Ltd(CIPLA | Returns |
|---|---|
1 Day Returns | 16.45% |
1 Month Returns | -5.23% |
3 Month Returns | 1.13% |
1 Year Returns | 28.63% |